CD274 and lung cancer: Their study reported lower kappa agreement results compared to ours (0.354 for uPath software, Roche, Basel, Switzerland and 0.672 for the PD-L1 Lung Cancer TME application—Visiopharm suite, Hoersholm, Denmark).